This site is intended for healthcare professionals

Negative results from phase III RESOLVE-1 study of lenabasum in patients with diffuse cutaneous systemic sclerosis .- Corbus Pharmaceutical Holdings Inc.

Read time: 1 mins
Last updated:13th Sep 2020
Published:13th Sep 2020
Condition: Systemic Sclerosis
Type: drug
Register free for full access to